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Abstract
Background: Motor and cognitive impairments are frequently observed following stroke, but are often managed as
distinct entities, and there is little evidence regarding how they are related. The aim of this study was to describe
the prevalence of concurrent motor and cognitive impairments 3 months after stroke and to examine how motor
performance was associated with memory, executive function and global cognition.
Methods: The Norwegian Cognitive Impairment After Stroke (Nor-COAST) study is a prospective multicentre cohort
study including patients hospitalized with acute stroke between May 2015 and March 2017. The National Institutes
of Health Stroke Scale (NIHSS) was used to measure stroke severity at admission. Level of disability was assessed by
the Modified Rankin Scale (mRS). Motor and cognitive functions were assessed 3 months post-stroke using the
Montreal Cognitive Assessment (MoCA), Trail Making Test Part B (TMT-B), 10-Word List Recall (10WLR), Short Physical
Performance Battery (SPPB), dual-task cost (DTC) and grip strength (Jamar®). Cut-offs were set according to current
recommendations. Associations were examined using linear regression with cognitive tests as dependent variables
and motor domains as covariates, adjusted for age, sex, education and stroke severity.
Results: Of 567 participants included, 242 (43%) were women, mean (SD) age was 72.2 (11.7) years, 416 (75%) had
an NIHSS score ≤ 4 and 475 (84%) had an mRS score of ≤2. Prevalence of concurrent motor and cognitive
impairment ranged from 9.5% for DTC and 10WLR to 22.9% for grip strength and TMT-B. SPPB was associated with
MoCA (regression coefficient B = 0.465, 95%CI [0.352, 0.578]), TMT-B (B = -9.494, 95%CI [− 11.726, − 7.925]) and
10WLR (B = 0.132, 95%CI [0.054, 0.211]). Grip strength was associated with MoCA (B = 0.075, 95%CI [0.039, 0.112]),
TMT-B (B = -1.972, 95%CI [− 2.672, − 1.272]) and 10WLR (B = 0.041, 95%CI [0.016, 0.066]). Higher DTC was associated
with more time needed to complete TMT-B (B = 0.475, 95%CI [0.075, 0.875]) but not with MoCA or 10WLR.
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Conclusion: Three months after suffering mainly minor strokes, 30–40% of participants had motor or cognitive
impairments, while 20% had concurrent impairments. Motor performance was associated with memory, executive
function and global cognition. The identification of concurrent impairments could be relevant for preventing
functional decline.
Trial registration: ClinicalTrials.gov Identifier: NCT02650531.
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Background
Stroke is reported to be the third-most common cause
of disability-adjusted life years (DALYs) worldwide [1].
Post-stroke motor and cognitive impairments are preva-
lent, and even though function improve during the first
3 months after stroke [2], approximately one fifth of
stroke patients experience stroke-related disability 3
months post-stroke [3], highlighting the need of early
detection and prevention of further deterioration of
function. Motor deficits leading to impaired gait, balance
and general reduction in physical function are seen in al-
most 50% of stroke cases 3 months after stroke [4]. The
prevalence of mild and major cognitive impairments ap-
pears to vary from 14 to 29% and 11 to 42%, respect-
ively, 3 months post-stroke, depending on the method
used to define post-stroke neurocognitive disorder [5].
In a study assessing stroke patients 3-6 months post-
stroke, Sachdev et al. reported a prevalence of mild cog-
nitive impairment and dementia of 37 and 21%, respect-
ively [6], underlining the importance of addressing
cognitive impairments following stroke.
Assessments of motor and cognitive functions have
established roles in the follow-up of stroke patients but
have traditionally been studied, diagnosed and managed
as distinct entities [7]. However, the stroke lesion itself,
comorbid cerebrovascular disease and neurodegenera-
tion may all cause both cognitive and motor impair-
ments [8].
It is well-documented that older people in the general
population with concurrent impairments in motor and
cognitive functions are at increased risk of developing
dementia as well as being at risk for higher rates of hos-
pital admissions, falls, dependency and mortality [7, 9,
10]. In population-based studies, the simultaneous pres-
ence of gait disturbances and memory complaints, called
motoric cognitive risk (MCR) syndrome, has also been
shown to increase risk of developing dementia [10].
Additionally, in the stroke population, impaired balance
and gait post-stroke are significant risk factors for cogni-
tive impairment [11, 12]. However, previous studies are
few in number, and there is a need for additional know-
ledge about the relationship between motor and cogni-
tive impairments based on multicentre studies of stroke
populations.
Previous research has clearly indicated an association
between cognitive and motor performance among older
people. Vascular pathology appears to be related to
motor impairments and executive dysfunction, while im-
paired memory is a typical symptom of neurodegenera-
tion, especially Alzheimer’s disease [13, 14]. Gait
performance following stroke has been reported to be
associated with global cognition, executive function and
memory [11, 12, 15]. The inability to combine a cogni-
tive task with a motor task like walking, assessed as
dual-task cost, has been proposed as an early marker of
dementia development [16]. However, studies of associa-
tions between motor function and different cognitive do-
mains in older populations have found divergent results
[10, 17–20], and there is little evidence in stroke popula-
tions. We hypothesized that motor performance would
be more closely related to executive function than to
memory in a stroke sample, reflecting vascular path-
ology. A recent consensus report recommended a mini-
mum core battery for assessing the motor-cognitive
interphase related to ageing and neurodegeneration in
order to increase comparability across research studies,
detect subtle or common reversible factors, and acceler-
ate research on dementia, falls, and ageing-related dis-
abilities [7]. This test battery included gait speed, dual-
task cost of gait speed (DTC-speed), the Montreal Cog-
nitive Assessment (MoCA) and the Trail Making Test
Parts A & B (TMT-A & -B) [21–23].
The overall aim of this study was to describe concur-
rent impairment in cognition and motor performance
and to explore how motor performance was related to




The Norwegian Cognitive Impairment After Stroke
(Nor-COAST) study is a prospective cohort study with
participants recruited from five different hospitals in
Norway between May 2015 and March 2017. The details
of the study have been published elsewhere [24]. Inclu-
sion criteria were as follows: a diagnosis of stroke ac-
cording to the WHO criteria [25] or findings on
magnetic resonance imaging (MRI) compatible with
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intracerebral haemorrhage or infarction; symptom onset
within 1 week of admission; age > 18 years; the ability to
communicate in Norwegian; and residing within the
catchment area of the participating hospitals. Patients
with expected survival < 3 months were excluded. The
present study is a cross-sectional sub-study of the Nor-
COAST study, utilizing data from the three-month
follow-up. In addition to the inclusion and exclusion cri-
teria for the Nor-COAST, the participants included in
the present study had to have completed at least one




The National Institutes of Health Stroke Scale (NIHSS)
[26] score at admission was used to measure stroke se-
verity; possible scores range 0–42, with a higher score
indicating a more severe stroke. Mild stroke was defined
as NIHSS score 0–4 points, for moderate stroke 5–12
points, for moderate to severe stroke 16–20 points and
for severe stroke > 20 points [4]. At three-moth follow-
up, instrumental activities of daily living (IADL) were
assessed with the Nottingham Extended Activities of
Daily Living (NEADL), a 0–66-point scale where a
higher score indicates greater independence [27], and
the inability to walk 200 m was used as an indicator of
physical frailty. Both assessments were based on infor-
mation collected through interview of patient or care-
giver. Functional dependency was measured with the
Modified Rankin Scale (mRS) [28], which comprises six
levels scored as 0–5 where 0 indicates no disability and
5 indicates severe disability; 6 is used to indicate death.
Prestroke score on mRS was recorded at baseline though
interview of caregivers, while status at 3 months was
assessed by interview of patient or caregiver at the hos-
pital outpatient clinic. The Charlson Comorbidity Index
[29] was used as a descriptive measure to quantify co-
morbidity among the participants and was based on par-
ticipant information and medical records collected at
baseline.
Motor performance tests
The Short Physical Performance Battery (SPPB), an as-
sessment of mobility, consists of three tasks: gait speed,
assessed by 4-m timed trials; balance, assessed by the
ability to stand for 10 s with the feet in three different
positions; and leg strength, measured by the time re-
quired for five sit-to-stand movements from a chair.
Each task is scored on a 4-point scale, with a total score
ranging 0–12 and higher scores indicating better func-
tion [30]. The cut-off for a score indicating impairment
was set at < 10 points [31]. To assess dual-task cost, the
participants were first asked to walk 10m at their
preferred gait speed, and then walk the same distance
while counting backwards [21]. Dual-task cost was cal-
culated using the formula ([single-task gait speed – dual-
task gait speed]/single-task gait speed × 100 = dual-task
cost) [16]; a reduction of more than 20% was character-
ized as impairment [16]. Grip strength was measured
with a Jamar Hydraulic Hand Dynamometer® (Lafayette
Instrument Europe, Loughborough, UK), and the highest
score of three attempts using the stronger hand was ap-
plied in the analyses. Scores < 21 kg were characterized
as impairment for women and < 37 kg for men [32].
Cognitive assessments
Global cognition was assessed with the Montreal Cogni-
tive Assessment (MoCA) with possible scores ranging
from 0 to 30 and higher scores indicating better cogni-
tion [23]. A cut-off for impairment was set at < 24
points, based on previous recommendations [33]. To as-
sess executive function, the Trail Making Test Part B
(TMT-B) [22] was applied. Taking more than 167 s (one
standard deviation [SD] below normative mean for the
age group 75–77 years) [34] to complete the test was de-
fined as executive dysfunction. The 10-Word List Recall
(10WLR), part of the 10-Word List Learning and Recall
from the Consortium to Establish a Registry for Alzhei-
mer’s Disease (CERAD) battery was applied to assess
memory; a score < 5 was defined as impairment, in line
with age-adjusted normative data [35, 36].
Data collection
Baseline characteristics were retrieved from participants,
their caregivers and medical records. Stroke diagnosis
and NIHSS scores were assessed by stroke physicians
during hospital stay. At three-month follow-up, partici-
pants were evaluated at a hospital outpatient clinic.
Motor and cognitive assessments were performed by
healthcare personnel who were trained to perform these
tests and according to a standardized manual.
Statistics
Demographic and clinical characteristics were summa-
rized using mean and SD for continuous variables and
frequencies and percentages for categorical variables.
For analyses of prevalence, the clinical variables were di-
chotomized based on predefined cut-offs and investi-
gated with cross tabulations between each of the motor
and cognitive tests. Associations were studied using lin-
ear regression with the continuous variables of the cog-
nitive tests as dependent variables and the motor
measures as independent variables. First, regression ana-
lyses were performed for each combination of motor
and cognitive assessments. Second, we conducted ana-
lyses for each of the cognitive tests one at a time, includ-
ing all three motor assessments, as independent
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variables. All regression analyses were adjusted for age,
sex, education and baseline NIHSS score, which had
been pre-defined as plausible confounders. Residuals
were checked for normality by visual inspection of Q-Q
plots. Statistical significance was defined as two-sided p-
value < 0.05, and 95% confidence intervals (CI) are re-
ported where relevant. Data were analyzed using IBM




Of 815 patients recruited to the Nor-COAST study, 700
were followed up at 3 months, and of these, 567 com-
pleted at least one motor and one cognitive assessment
(Fig. 1). The mean (SD) age of the study participants was
72.2 (11.7) years; 242 (43%) were women; and 460 (82%)
were diagnosed with ischemic stroke. Baseline mean
(SD) NIHSS score was 3.7 (4.7), and 416 (75%) of the
participants had NIHSS scores ≤4 points, indicating
minor strokes (Table 1). The pre-stroke modified Rankin
Scale (mRS) score was ≤2 in 533 (94%) of the partici-
pants, and after 3 months, 475 (84%) had an mRS
score ≤ 2 (Table 1). As compared to study participants,
those lost to follow-up were significantly older (mean
[SD] age 78.5 [10.6], p-value < 0.001) and had suffered
more severe strokes (mean [SD] NIHSS score 6.9 [7.8],
p-value < 0.001), but there were no differences in sex.
Prevalence of motor and cognitive impairments
Scores for the motor and cognitive tests are presented in
Table 2. SPPB scores < 10 points were found in 210
(37%) participants, indicating reduced mobility. DTC ≥
20% was measured in 146 (29%) participants, indicating
a clinically relevant reduction in dual task capacity, while
grip strength was below cut-off in 97 (45%) of the
women and 120 (39%) of the men, indicating a clinically
relevant reduction of strength. On the cognitive tests,
185 (33%) scored below 24 points on the MoCA, indicat-
ing reduced global cognition; TMT-B > 167 s indicated
impaired executive function in 194 (37%); and 10WLR
score below five showed impairment in memory in 188
(39%) of the participants.
Regarding the prevalence of concurrent impairment,
dual-task cost in combination with each of the cognitive
tests showed a prevalence of approximately 10% (range
9.5–11.3%). The other combinations of tests resulted in
reduced scores for both the cognitive and motor tests in
about one-fifth of the participants (range 18.6–22.9%)
(Fig. 2). Of the participants who scored below 24 points
on the MoCA, 103 (57%) scored below 10 points on the
SPPB, and of those who took more than 167 s to
complete the TMT-B or could not complete it, 102
(54%) scored below 10 points on the SPPB (Fig. 2).
Associations between motor and cognitive function
As shown in Table 3, the regression analyses showed
that both the SPPB score and grip strength were associ-
ated with scores on the MoCA (p < 0.001), TMT-B (p <
0.001) and 10WLR (p = 0.001). For example, the esti-
mated regression coefficient B = 0.465 for SPPB with
MoCA as dependent variable means that for two individ-
uals with the same age, sex, education and stroke sever-
ity (NIHSS score at admission), and with one score
Fig. 1 Flow chart on inclusion
Einstad et al. BMC Geriatrics          (2021) 21:103 Page 4 of 10
difference in SPPB, the expected difference in MOCA is
0.465. The DTC was associated only with the score on
the TMT-B (p = 0.005). These associations remained sta-
tistically significant in the adjusted model (Table 4).
Discussion
In this cross-sectional study of survivors who had suf-
fered mainly mild strokes, we found impairments in ei-
ther cognitive function or motor function in about one-
third of patients, while the prevalence of concurrent im-
pairment ranged from 10 to 23%, depending on which
combination of motor and cognitive domains were
assessed. Impairments in mobility and grip strength were
associated with impaired global cognition, executive dys-
function and impaired memory. Higher dual-task cost
was associated only with executive dysfunction. The
identification of concurrent impairments could be rele-
vant for preventing functional decline and should en-
courage a holistic approach to this patient group.
The scores on post-stroke cognitive tests identifying
impairment shown here are in line with the results of
previous studies [37]. A trend of reduced mobility 3
months post-stroke, especially in patients having suf-
fered from moderate stroke, has been described [38],
and Vahlberg et al. [39] found SPPB scores in line with
finding from the present study, which are lower than re-
ported in the general population [40]. Motor function
has been reported to be a significant predictor of
Table 1 Baseline characteristics
n
Demographics
Age, years, mean (SD) 567 72.2 (11.7)
Females, n (%) 567 242 (42.7%)
Living alone, n (%) 564 195 (34.4%)
Education > 9 years, n (%) 567 424 (74.8%)
Stroke classification
Infarction, n (%) 558 460 (82.4)
Haemorrhage, n (%) 558 51 (9.0%)
Not classified, n (%) 558 47 (8.3%)
NIHSS score at admittance (0–42), mean (SD) 553 3.7 (4.7)
NIHSS score at admittance
Mild stroke (0–4), n (%) 553 416 (75.2%)
Moderate stroke (5–15), n (%) 553 113 (20.4%)
Moderate to severe stroke (16–20), n (%) 553 20 (3.5%)
Severe stroke (> 20), n (%) 553 4 (0.7%)
Charlson Comorbidity Index, baseline (0–24), mean (SD) 567 3.9 (1.9)
Antiplatelet treatment at discharge, n (%) 567 388 (68.4%)
Anticoagulation treatment at discharge, n (%) 567 166 (29.3%)
mRS (0–6), pre-stroke, mean (SD) 565 0.7 (0.9)
SD standard deviation, NIHSS National Institutes of Health Stroke Scale, (0-42p), mRS Modified Rankin Scale (0-6p)
Table 2 Assessments at three-month follow-up
n
Assessments of motor performance
SPPB (0–12), mean (SD) 563 9.4 (3.1)
Dual-task cost, (%), mean (SD) 500 12.3 (16.2)
Grip strength (kg), mean (SD)
Men 305 40.1 (11.7)
Women 216 21.7 (6.9)
Gait speed 4m, (m/s), mean (SD) 550 1.0 (0.3)
Assessments of cognitive performance
MoCA (0–30), mean (SD) 562 23.8 (4.7)
TMT-B (0–300), mean (SD) 525 154.7 (83.9)
10-Word List Recall (0–10), mean (SD) 484 5.2 (2.7)
Assessments of function
Able to walk 200 m, 3 months, n (%) 527 485 (92.0%)
mRS (0–6), 3 months, mean (SD) 565 2.0 (1.3)
Nottingham EADL (0–66), 3 months, mean (SD) 553 49.0 (13.0)
SD standard deviation, SPPB Short Physical Performance Battery (0-12p), Dual-
task cost ([single-task gait speed – dual-task gait speed]/single-task gait speed
× 100) (0–100%), MoCA Montreal Cognitive Assessment (0-30p), TMT-B Trail
Making Test Part B (0–300 s), 10-Word List Recall the recall part of the 10-Word
List Learning and Recall from the CERAD (Consortium to Establish a Registry
for Alzheimer’s Disease) Battery (0–10 words), mRS Modified Rankin Scale,
Nottingham EADL Nottingham Extended Activities of Daily Living scale (0-66p)
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cognitive decline after stroke [12]. However, associations
between motor performance and cognitive domains have
not, to the best of our knowledge, been examined previ-
ously in stroke samples. The dual-task cost has been rec-
ommended as a valid measure of the motor-cognitive
interphase [41] and found to predict incident dementia
in individuals with mild cognitive impairment without
previous history of stroke [16]. Several studies of elderly
persons with cognitive impairment have shown a strong
association between the dual-task test and global cogni-
tion [10, 19], but this was not supported by a study of
patients with Parkinson’s disease [42]. In the present
study, dual-task cost was associated only with executive
function.
Fig. 2 Prevalence of motor and cognitive impairments. MoCA Montreal Cognitive Assessment; SPPB Short Physical Performance battery; Dual-task
cost ([single-task gait speed – dual-task gait speed]/single-task gait speed × 100); TMT-B Trail Making Test Part B. Impaired performance was
defined as: MoCA <24p, TMT-B > 167 s, 10-Word List Recall < 5 words, SPPB < 10 p, Dual-task cost > 20% and grip strength < 21 kg (women)
and < 37 kg (men)
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In the present study, we have demonstrated that, al-
though the patients suffered mainly mild strokes with
low NIHSS scores, cognitive and motor impairments as
well as concurrent impairments are prevalent, as the ma-
jority of patients with impaired MoCA scores also had
impaired SPPB scores and vice versa. Concurrent motor
and cognitive impairments have been shown to predict
poor prognosis as, for example, an increased risk of
developing dementia in stroke-free populations [43, 44],
and there is reason to believe that these impairments
can impact recovery and everyday life [45]. Therefore,
we believe that, as part of the routine follow-up protocol
after stroke, assessments of cognition and global motor
functions should be performed to gain more information
that may be relevant for prognosis and may indicate a
need for continued rehabilitation even 3 months after a
stroke [45]. Further cognitive function is very important
for planning and performing rehabilitation and cognitive
impairment, such as impaired memory or executive dys-
function, might change responsiveness to motor re-
habilitation, which should be taken into consideration
when developing targeted interventions in stroke popu-
lations [46]. We did not find support for motor perform-
ance being more closely associated with specific
cognitive domains, and we suggest using global tests like
MoCA and SPPB in order to assess cognitive and motor
function.
Shared underlying pathologies might explain concur-
rent impairment in cognition and motor performance,
for which there is increasing evidence [9]. Theoretically,
the impairments can be caused directly by the stroke le-
sion or by structural and functional impairments that
appear at a distance from the stroke lesion, also known
as diaschisis [47]. Previous studies have shown that
stroke survivors have small-vessel disease and neurode-
generation in addition to focal stroke lesions [48, 49],
and small-vessel disease and neurodegenerative disease
are both reported to be associated with impairments in
gait and balance as well as cognition [8, 50–52]. Conse-
quently, the observed impairments in motor and cogni-
tive functions may be a symptom of both focal and
disseminated brain pathology. The lack of findings of
distinct associations could support a hypothesis of mixed
pathology, but further research, including neuroimaging,
is needed to achieve better insight.
The strengths of this work are the multicentre design,
a relatively large sample size, and the comprehensive test
battery that has been performed in line with consensus
guidelines [7]. It is also a strength that the Nor-COAST
participants are shown to be representative of the major-
ity of the Norwegian stroke population that suffers from
mild strokes [53]. Compared to the Norwegian Stroke
Registry, the participants included in this sub-study were
slightly younger (72 vs 73 years) with a larger proportion
suffering from minor impairments (75% vs 69%) mea-
sured by baseline NIHSS scores [4]. Despite relatively
wide inclusion criteria, there was a selection bias to-
wards younger stroke patients with milder strokes. As a
result, this sub-sample probably comprises those individ-
uals most likely to benefit from interventions designed
to prevent further functional decline and may be gener-
alized to this part of the stroke population. The
Table 3 Regression analyses with one motor domain at a time
as covariatea
Regression coefficient
n B p-value 95% CI
MoCA
SPPB 539 0.465 < 0.001 0.352, 0.578
Dual-task cost 485 −0.004 0.661 −0.023, 0.015
Grip strength 503 0.075 < 0.001 0.039, 0.112
TMT-B
SPPB 507 −9.494 < 0.001 −11.726, −7.925
Dual-task cost 468 0.475 0.005 0.075, 0.875
Grip strength 479 −1.972 < 0.001 −2.672, − 1.272
10-Word List Recall
SPPB 464 0.132 0.001 0.054, 0.211
Dual-task cost 430 0.000 0.951 −0.014, 0.015
Grip strength 446 0.041 0.001 0.016, 0.066
MoCA Montreal Cognitive Assessment, SPPB Short Physical Performance
Battery, Dual-task cost ([single-task gait speed – dual-task gait speed]/single-
task gait speed × 100), TMT-B Trail Making Test Part B
aadjusted for age, sex, education and stroke severity (NIHSS score
at admission)
Table 4 Regression analyses with all motor domains as
covariates in the same modela
Regression coefficient
B p-value 95% CI
MoCA (n = 463)
SPPB 0.309 < 0.001 0.179, 0.438
Dual-task cost −0.006 0.497 −0.025, 0.012
Grip strength 0.063 < 0.001 0.028, 0.097
TMT-B (n = 448)
SPPB −8.588 < 0.001 −11.204, −5.972
Dual-task cost 0.499 0.009 0.124, 0.873
Grip strength −1.613 < 0.001 −2.296, −0.930
10-Word List Recall (n = 417)
SPPB 0.099 0.048 0.001, 0.198
Dual-task cost −0.002 0.786 −0.017, 0.013
Grip strength 0.036 0.010 0.010, 0.061
MoCA Montreal Cognitive Assessment, SPPB Short Physical Performance
Battery, Dual-task cost ([single-task gait speed – dual-task gait speed]/single-
task gait speed × 100), TMT-B Trail Making Test Part B
aadjusted for age, sex, education and stroke severity (NIHSS score
at admission)
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prevalence of impairments reported in this study is
closely related to the choice of test battery and cut-off
values, which are in line with current recommendations
[7]. For MoCA, the cut-off for impairment was set at <
24 points, [33, 54] which should also detect patients with
mild cognitive impairment in this population with eld-
erly stroke patients. Because of the large scale of the
study, we used a standardized protocol for dual-task cost
with counting backwards. This could represent a meth-
odological limitation in this heterogeneous sample, and
individual adjustments such as applying more-complex
cognitive tasks or motor performance tests could have
resulted in other findings [55] but were deemed beyond
the scope of this multicentre study. Lastly, the cross-
sectional design of the study limits any conclusions in
regard to causality.
Conclusion
We found subtle cognitive and motor impairments and
combinations of these to be relatively common among
stroke survivors despite high premorbid functioning and
minor strokes. Motor performance was associated with
memory, executive function and global cognition. Our
findings add knowledge about post-stroke motor and
cognitive function and highlight the need for awareness
of motor and cognitive impairments in stroke popula-
tions. Further research is needed in regard to the prog-
nostic significance of our findings, as well as their
associations to underlying pathology. Concurrent im-
pairments should be recognized both in a short- and
long-term perspective in order to identify and target
those patients in need of prolonged rehabilitation to pre-
vent further functional decline.
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